[Pre and postoperative chemotherapy of XXXX with an adriamycin-cisplatin combination. Risks of a neoadjuvant chemotherapy which is not sufficiently effective].

@entity1 @entity39 @entity5 @entity421 @entity158
The authors evaluated a new protocol of neoadjuvant chemotherapy for @entity421 , easier to manage and different from T10. The good results obtained with the postoperative ADR-CDDP association led us to undertake a pilot study between 1982 and 1984, using ADR-CDDP as preoperative chemotherapy. The records of sixteen @entity1 were available for follow-up. The average age of the @entity1 was 19.9 years. @entity1 received two or three preoperative courses, and a total of six identical courses. Tolerance was good. @entity158 usually disappeared but this was often misleading because associated with radiological and/or clinical @entity5 progression, low histological @entity39 or poor outcome. The continuous disease-free survival actuarial rate was less than 57 and 40% at 18 months and two years respectively. The actuarial survival rate was 87% at one year and 65% at two years respectively. Disappointing results of this preoperative protocol, compared to results with the SO4 78 or T10 protocols for example, led to publish these data early in order to underline their potential dangers. As a result, we stopped our study. The charter of pilot studies justifies this publication. As well, these data point out the necessity of very close follow-up of neoadjuvant chemotherapy by sophisticated medical imaging. Neoadjuvant chemotherapy, if ineffective, must be stopped early, and should lead to surgery, followed by adequate postoperative chemotherapy.
